Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
77.40
-0.19 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
June 22, 2023
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
June 05, 2023
Via
ACCESSWIRE
Moderna to Present at Upcoming Conferences in June 2023
June 01, 2023
Via
ACCESSWIRE
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
May 30, 2023
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in Tuesday Morning Trading
May 23, 2023
Via
Investor Brand Network
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
May 19, 2023
Via
ACCESSWIRE
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
May 02, 2023
Via
ACCESSWIRE
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
April 20, 2023
Via
ACCESSWIRE
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
April 11, 2023
Via
ACCESSWIRE
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
March 10, 2023
Via
ACCESSWIRE
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Is Novavax Finally Turning Things Around?
May 15, 2023
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea
Via
MarketBeat
Exposures
COVID-19
3 Underperforming Nasdaq 100 Stocks Worth a Closer Look
May 04, 2023
Given the volatility and growth potential associated with the Nasdaq’s elite, investors may want to keep these recent underperformers on the watch list.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
February 23, 2023
Via
ACCESSWIRE
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
Via
ACCESSWIRE
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
May 03, 2023
Via
ACCESSWIRE
6 Best Healthcare Stocks to Buy Right Now
April 25, 2023
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat.
Via
MarketBeat
Topics
Economy
Intellectual Property
Exposures
Economy
Intellectual Property
Product Safety
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
April 20, 2023
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
April 16, 2023
Via
ACCESSWIRE
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV
April 06, 2023
Via
ACCESSWIRE
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
March 30, 2023
Via
ACCESSWIRE
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
March 24, 2023
Via
ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
March 23, 2023
Via
ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
March 23, 2023
From
Generation Bio Co.; Moderna
Via
GlobeNewswire
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
March 20, 2023
By Ernest Dela Aglanu, Benzinga
Via
TheNewswire.com
Topics
Death
Economy
Exposures
COVID-19
Death
Economy
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
March 14, 2023
Via
ACCESSWIRE
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
February 28, 2023
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna to Present at Cowen's 43rd Annual Health Care Conference
February 28, 2023
Via
ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
February 22, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.